Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Sanofi Presents New Data for an Investigational Fixed-Ratio Combination of Insulin Glargine and Lixisenatide at the European Association for the Study of Diabetes 52nd Annual Meeting

Sanofi
Posted on: 16 Sep 16

Guildford, United Kingdom – 14 September, 2016 - Sanofi announced today new data supporting a fixed-ratio combination of insulin glargine and lixisenatide to be presented at the European Association for the Study of Diabetes 52nd Annual Meeting in Munich, Germany.

 

There are currently 3.5 million people in the UK diagnosed with diabetes[i] a figure predicted to rise to an estimated five million people by 2025.1 Over two thirds of adults treated with insulin do not reach the National Institute for Health and Care Excellence (NICE) target for blood glucose control (HbA1c ≤ 7.5%),[ii] increasing their risk of potentially avoidable complications such as amputation, blindness and renal disease.1

 

Dr Mike Baxter, medical therapy expert at Sanofi UK said, “Blood glucose management in the UK is amongst the worst in Europe with, on average, people with type 2 diabetes having the highest blood glucose levels compared to nine other developed countries. This latest study reflects Sanofi’s ongoing commitment to innovative approaches in developing medicines that are intended to help patients manage their condition and reduce the risk of avoidable complications”.

 

New results from the LixiLan-L study, a trial investigating a titratable fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide (iGlarLixi) in adults with type 2 diabetes, showed in patients with type 2 diabetes (T2D) uncontrolled with basal insulin, the fixed-ratio combination demonstrated greater post meal glycaemic control compared with insulin glargine alone, with consistently more patients reaching postprandial plasma glucose (PPG) targets after all meals throughout the day.[iii]

 

The study will be presented at the European Association for the Study of Diabetes 52nd Annual Meetings:

·         Postprandial glycaemic outcomes of a fixed-ratio combination of insulin glargine and lixisenatide in the LixiLan-L trial (Vidal, J et al. Poster presentation 801, European Association for the Study of Diabetes 52nd Annual Meeting, Munich, Germany at Tues. 13 Sept, 13:15 - 14:15)

 

The fixed dose combination of insulin glargine and lixisenatide is currently undergoing licensing review by the European Medicines Agency (EMA).

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 16/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.